Among the molecular features characteristic of these proposed subclassifications, the presence or absence of IDH mutations in GBM has been one of the earliest molecular changes to become incorporated explicitly into any diagnostic designation in the WHO. This evidence concerns the gene IDH1 and glioblastoma.